✨ Your Portfolio is fetched and updated from zerodha.
Nano Pharmaceuticals
Market Cap
₹8 Cr.
P/E
364.64
  • Hind Bio Science
  • Senbo Industries
  • Kobo Biotech

FAQs on Hindustan Bio Sciences Ltd. Shareprice

Hind Bio Science has given better returns compared to its competitors.
Hind Bio Science has grown at ~15.81% over the last 9yrs while peers have grown at a median rate of 1.78%

Hind Bio Science is expensive when considering the PE ratio, however latest EV/EBIDTA is < 3 yr avg EV/EBIDTA.
Latest PE of Hind Bio Science is 362, while 3 year average PE is 74.8.
Also latest EV/EBITDA of Hind Bio Science is 0.0 while 3yr average is 301.

Growth Table

  • Hindustan Bio Sciences Ltd.
  • Senbo Industries
  • Kobo Biotech

Balance Sheet

  • Hindustan Bio Sciences Ltd.
  • Senbo Industries
  • Kobo Biotech

Balance Sheet Snapshot

No data available.

Fund Flow Analysis

  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
*Data is as of latest FY end

Profit & Loss

  • Hindustan Bio Sciences Ltd.
  • Senbo Industries
  • Kobo Biotech

Cash Flow

  • Hindustan Bio Sciences Ltd.
  • Senbo Industries
  • Kobo Biotech

Cash Flow Analysis

  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.

Ratios

= Dominant Factor
  • Hindustan Bio Sciences Ltd.
  • Senbo Industries
  • Kobo Biotech

Quarterly Results

  • Hindustan Bio Sciences Ltd.
  • Senbo Industries
  • Kobo Biotech

Reverse DCF

locked
Cr
locked
5 YEAR
locked 5
10 YEAR
locked 10
20 YEAR
locked 20
Implied Growth Rate over a 5 year period*
Implied Growth Rate over a 10 year period*
Implied Growth Rate over a 20 year period*

FAQs on Hindustan Bio Sciences Ltd. Financials

Hind Bio Science balance sheet is weak and might have solvency issues

Yes, The net debt of Hind Bio Science is increasing.
Latest net debt of Hind Bio Science is ₹2.6 Crs as of Sep-25.
This is greater than Mar-25 when it was ₹2.48 Crs.

Yes, profit is increasing.
The profit of Hind Bio Science is ₹0.1 Crs for Mar 2025, ₹0.06 Crs for Mar 2024 and -₹0.04 Crs for Mar 2023

The company seems to be paying a very low dividend.
Investors need to see where the company is allocating its profits.
Hind Bio Science latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%

Companies resources are allocated to majorly unproductive assets like Short Term Loans & Advances

Ideas Dashboard
Results
Timeline
Watchlist
Portfolio
Alerts
Stock Screener
Market
Raw Material
Data feed provided by Accord Fintech